DiabetologyNews.net

Diabetology Xagena

The pivotal inTandem1 phase 3 clinical trial of Sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a backgroun ...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at the American Diabetes Association ( ADA ) 76th Scientific S ...


Recent guidelines governing anti-diabetic medications increasingly advocate Metformin as first-line therapy in all patients with type 2 diabetes. However, Metformin could be associated with increased ...


New analyses have shown risk reductions were consistent across age groups for cardiovascular outcomes, including cardiovascular death, with Empagliflozin ( Jardiance ) compared with placebo when added ...


New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in people with type 2 diabetes with establis ...


The FDA ( Food and Drug Administration ) has required labeling changes regarding the recommendations for Metformin-containing medicines for diabetes to expand Metformin’s use in certain patients with ...


The FDA ( Food and Drug Administration ) has found that type 2 diabetes medicines containing Saxagliptin and Alogliptin may increase the risk of heart failure, particularly in patients who already hav ...


New data from a clinical trial led by cardiologists at Brigham and Women's Hospital ( BWH ) and the Duke Clinical Research Institute indicates that the non-statin, cholesterol-lowering drug Ezetimibe ...


The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The trial investigated the efficacy and safety of 0.5 mg and 1.0 m ...


Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug Sitagliptin ( Januvia ) without an increased risk of cardiovascular complications, even if they have ...


Positive top-line results from EMPA-REG OUTCOME were announced. This is a long-term clinical trial investigating cardiovascular ( CV ) outcomes for Jardiance ( Empagliflozin ) in more than 7,000 adult ...


The aim of a study was to identify risk factors for the development of statin-associated diabetes mellitus ( DM ). The study was conducted in two phases. Phase one involved high-throughput in silic ...


In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes ( T1D ), led by UC San Francisco researchers and physicians, patients experienced no serious adverse reactions after r ...


Reliable quantification of the association between blood pressure and risk of type 2 diabetes mellitus is lacking. A study sought to determine the association between usual blood pressure and risk of ...


Empagliflozin ( Jardiance ) has significantly reduced the risk of the combined endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 14% when added to standard of ca ...